ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 140 filers reported holding ACCELERON PHARMA INC in Q1 2017. The put-call ratio across all filers is 2.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $57,000 | +78.1% | 1,063 | +33.9% | 0.00% | – |
| Q3 2019 | $32,000 | +10.3% | 794 | +17.1% | 0.00% | – |
| Q2 2019 | $29,000 | -9.4% | 678 | 0.0% | 0.00% | – |
| Q1 2019 | $32,000 | +23.1% | 678 | +17.3% | 0.00% | – |
| Q4 2018 | $26,000 | +225.0% | 578 | +328.1% | 0.00% | – |
| Q3 2018 | $8,000 | +33.3% | 135 | -1.5% | 0.00% | – |
| Q2 2018 | $6,000 | 0.0% | 137 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | 0.0% | 137 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | +50.0% | 137 | +44.2% | 0.00% | – |
| Q3 2017 | $4,000 | +33.3% | 95 | 0.0% | 0.00% | – |
| Q2 2017 | $3,000 | +50.0% | 95 | 0.0% | 0.00% | – |
| Q1 2017 | $2,000 | -50.0% | 95 | -18.8% | 0.00% | – |
| Q4 2016 | $4,000 | 0.0% | 117 | +3.5% | 0.00% | – |
| Q3 2016 | $4,000 | – | 113 | +769.2% | 0.00% | – |
| Q2 2016 | $0 | – | 13 | 0.0% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 13 | -53.6% | 0.00% | – |
| Q4 2015 | $1,000 | – | 28 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |